Vertex Pharmaceuticals (VRTX) Operating Expenses (2009 - 2026)

Vertex Pharmaceuticals' Operating Expenses history runs 18 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• On a quarterly basis, Operating Expenses fell 13.61% year-over-year to $1.8 billion in Q1 2026; TTM through Mar 2026 was $7.5 billion, a 36.36% decrease from a year earlier, with the FY2025 full-year figure at $7.8 billion, down 30.44% from the prior year.
• Operating Expenses declined to $1.8 billion in Q1 2026 per VRTX's latest filing, from $2.0 billion in the prior quarter.
• Across five years, Operating Expenses topped out at $6.2 billion in Q2 2024 and bottomed at $1.1 billion in Q1 2022.
• The 5-year median for Operating Expenses is $1.6 billion (2023), against an average of $1.9 billion.
• Across the five-year window, Operating Expenses surged 319.98% in 2024 and plunged 70.56% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $1.3 billion in 2022, then rose by 20.49% to $1.5 billion in 2023, then increased by 23.33% to $1.9 billion in 2024, then grew by 5.2% to $2.0 billion in 2025, then dropped by 6.82% to $1.8 billion in 2026.
• Per Business Quant, the three latest VRTX Operating Expenses figures stand at $1.8 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.9 billion (Q3 2025).